Basic information
- CAS
346-18-9- Standard SMILES
CN1C(CSCC(F)(F)F)Nc2cc(Cl)c(S(N)(=O)=O)cc2S1(=O)=O- InChIKey
CYLWJCABXYDINA-UHFFFAOYSA-N- Molecular formula
- C11H13ClF3N3O4S3
- Average molar mass
- 439.9 g/mol
- Monoisotopic mass
- 438.9708816
Overview
Crystals or white powder. (NTP, 1992)
Names & identifiers
- Preferred name
- Polythiazide
- IUPAC
- 6-chloro-2-methyl-1,1-dioxo-3-(2,2,2-trifluoroethylsulfanylmethyl)-3,4-dihydro-1λ6,2,4-benzothiadiazine-7-sulfonamide
- English name
- POLYTHIAZIDE (200 MG)
- Molecular formula
- C11H13ClF3N3O4S3
- Molecular weight
- 439.8818296
Names & synonyms
Renese346-18-9DrenusilNephrilPolitiazidaP-2525DTXSID6025939P 2525NSC-1081612H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-, 1,1-dioxide36780APV5N6-Chloro-3,4-dihydro-2-methyl-3-(((2,2,2-trifluoroethyl)thio)methyl)-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide
Show more names
polythiazidep2525DrenusilnephrilPOLYTHIAZIDE (200 MG)Polythiazide Solution, 100ppm
DTXCID8059392-Methyl-3-(beta,beta,beta-trifluoroethylthiomethyl)-6-chloro-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-, 1,1-dioxideNSC1081616-Chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxidepolitiazide6-chloro-2-methyl-1,1-dioxo-3-(((2,2,2-trifluoroethyl)sulfanyl)methyl)-3,4-dihydro-2H-1$l^(6),2,4-benzothiadiazine-7-sulfonamide6-chloro-2-methyl-1,1-dioxo-3-{[(2,2,2-trifluoroethyl)sulfanyl]methyl}-3,4-dihydro-2H-1$l^{6},2,4-benzothiadiazine-7-sulfonamide
Properties
Computed structural properties
- XLogP
- 2.6
- Topological polar surface area
- 152 Ų
- Hydrogen bond donors
- 2
- Hydrogen bond acceptors
- 11
- Rotatable bonds
- 4
- Heavy atoms
- 25
- Formal charge
- 0
- Complexity
- 692
Experimental & physicochemical properties
DrugsPharmaceuticals -> Cardiovascular system -> Diuretics
LogP
log Kow = 1.90
1.90
1.9
Color/Form
WHITE, CRYSTALLINE POWDER
CRYSTALS FROM ISOPROPANOL
Solubility
less than 1 mg/mL at 68 °F (NTP, 1992)
PRACTICALLY INSOL IN WATER & CHLOROFORM; SOL IN METHANOL, ACETONE & DIMETHYLFORMAMIDE
SOL IN AQ SOLN MADE ALKALINE WITH CARBONATES OR HYDROXIDES OF ALKALI METALS
2.64e-01 g/L
Human Drugs
Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Thiazide Diuretics
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Pharmaceuticals
DecompositionWhen heated to decomp ... emits very toxic fumes of /hydrogen chloride, hydrogen fluoride/, sulfoxides, and nitroxides.
Melting Point
396.5 °F (NTP, 1992)
202.5 °C
Safety & regulation
Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.
GHS classification
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 38 reports by companies from 1 notifications to the ECHA C&L Inventory.
Hazard information
Regulatory Information2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3,4-dihydro-2-methyl-3-(2,2,2-trifluoroethyl)thiomethyl-, 1,1-dioxide: Does not have an individual approval but may be used under an appropriate group standard
Fire HazardsFlash point data for this material are not available, but it is probably combustible. (NTP, 1992)
Health Hazards
SYMPTOMS: Symptoms of exposure to related compounds include lethargy, muscle cramps, acidosis, gastric upset, skin rash, salivary gland obstruction, psychosis, convulsions, hyperuricemia, leukopenia, jaundice, increased hepatic decompensation in hepatic cirrhosis; photosensitization, precipitation or aggravation of diabetes mellitus; ulceration of small intestine from combined therapy with potassium chloride; hypercalcemia, and rarely glomerulonephritis, pancreatitis, thrombocytopenic pupura or agranulocytosis.
FDA Requirements
Manufacturers, packers, and distributors of drug and drug products for human use are responsible for complying with the labeling, certification, and usage requirements as prescribed by the Federal Food, Drug, and Cosmetic Act, as amended (secs 201-902, 52 Stat. 1040 et seq., as amended; 21 U.S.C. 321-392).
Reactive GroupAmines, Phosphines, and Pyridines
Chemistry & industry
Pharmacology
ATC Code
C - Cardiovascular system
QC - Cardiovascular system
Pharmacodynamics
As a thiazide diuretic, Polythiazide inhibits the sodium-chloride symporter which decreases solute reabsorption leading to a retention of water in the urine, as water normally follows solutes. More frequent urination is due to the increased loss of water that has not been retained from the body as a result of a concomitant relationship with sodium loss from the convoluted tubule. The short-term anti-hypertensive action is based on the fact that thiazides decrease preload, decreasing blood pressure
Mechanism of Action
As a diuretic, polythiazide inhibits active chloride reabsorption at the early distal tubule via the thiazide-sensitive Na-Cl cotransporter (TSC), resulting in an increase in the excretion of sodium, chloride, and water. Thiazides like polythiazide also inhibit sodium ion transport across the renal tubular epithelium through binding to the thiazide sensitive sodium-chloride transporter. This results in an increase in potassium excretion via the sodium-potassium exchange mechanism. The antihypertensive mechanism of polythiazide may be mediated through its action on carbonic anhydrases in the smooth muscle or through its action on the large-conductance calcium-activated potassium (KCa) channel, also found in the smooth muscle.
DOMINANT ACTION OF THIAZIDES IS TO INCR RENAL EXCRETION OF SODIUM & CHLORIDE & ACCOMPANYING VOL OF WATER. THIS EFFECT IS VIRTUALLY INDEPENDENT OF ACID-BASE BALANCE. /BENZOTHIADIAZIDE DIURETICS/
RENAL ACTIONS OF THIAZIDE DIURETICS DECR EXTRACELLULAR FLUIDS & PLASMA VOL, CARDIAC OUTPUT, & TOTAL EXCHANGEABLE SODIUM IN INDIVIDUALS WITHOUT ANY EVIDENCE OF CARDIAC FAILURE. AT THIS STAGE, SODIUM & WATER DEPLETION APPEARS TO PROVIDE ADEQUATE BASIS FOR ANTIHYPERTENSIVE EFFECT... /BENZOTHIADIAZIDE DIURETICS/
GLOMERULAR FILTRATION RATE MAY BE REDUCED BY THIAZIDES... THIS IS PRESUMABLY RESULT OF DIRECT ACTION ON RENAL VASCULATURE. ...THIAZIDES DECR RENAL EXCRETION OF CALCIUM RELATIVE TO THAT OF SODIUM, SINCE ITS REABSORPTION IS UNAFFECTED IN DISTAL NEPHRON WHEREAS THAT OF SODIUM IS BLOCKED. /BENZOTHIADIAZIDE DIURETICS/
BECAUSE HEMODYNAMIC MEASUREMENTS INDICATE THAT PERIPHERAL VASCULAR RESISTANCE IS DECR BY THIAZIDES, DIRECT ACTION OF THESE DRUGS ON ARTERIOLAR SMOOTH MUSCLE HAS BEEN SUGGESTED. /BENZOTHIADIAZIDE DIURETICS/
Related reactions
0 records
No reaction records under the current filter.
Compound notes
Loading…